I recommend P&G switch to the EDC option. Although it requires an investment in computers and training, it is clearly the only option that drastically cuts down on the time in data processing which ultimately leads to greater revenue growth for the company. More specifically, the consultants presented a flow chart that indicated the trial process could be reduced from 8 weeks to 4 weeks!
That said, there are several things to consider before, during and after adapting to an electronic system. The costs for the materials and training should be budgeted and the customer and user support systems should be developed. Once completed, the EDC system is likely to greatly increase the speed with which clinical trials are processed. As this process becomes more time efficient, more trials can be run which means P&G Pharmaceuticals can expect significant financial growth. With EDC, P&G will be ahead of the competitive curve and be able to compete as the pharmaceutical industry expands into the wide world of technology.

No comments:
Post a Comment